Emboline expects that its technology designed to reduce stroke risk during structural heart procedures will launch in the US and Europe later this year.

Emboline has secured $20 million for its embolic protection system, designed to minimize stroke risk associated with transcatheter aortic valve replacement procedures. The Santa Cruz, CA-based company ...

United States Embolic Protection Device Market is expected to reach US$ 650 million by 2033 from US$ 360 million in 2024, with a CAGR of 6.96% from 2025 to 2033. Rising cardiovascular operations, ...

Emboline, Inc., a privately held medical technology company focused on reducing stroke and ischemic damage during structural heart ...

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

Please provide your email address to receive an email when new articles are posted on . In patients having TAVR, cerebral embolic protection reduced risk for periprocedural stroke in patients from the ...

Transcatheter aortic valve replacement (TAVR) is revolutionizing the treatment of aortic valve stenosis, offering a minimally invasive option for patients suffering from this heart condition. However, ...

LONDON — Two years after the large multinational PROTECTED TAVR trial failed to associate a cerebral embolic protection (CEP) device with significant protection from stroke in patients undergoing ...

(MENAFN- EIN Presswire) EINPresswire/ -- The Embolic Protection Devices Market is gaining significant traction globally, driven by the rising prevalence of cardiovascular diseases, increasing adoption ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...